NEURO61

Presentation information

[held on paper]Oral Session

[O-31] Oral Session 31
Clinical trial and Regenerative medicine 1 E

[O-31-9] Pooled analysis from the SAkura trials with satralizumab in neuromyelitis optica spectrum disorder

Jerome De Seze1, Brian G. Weinshenker2, Yusuke Terada3, Yuichi Kawata3, Athos Gianella-borradori4, H.-christian Von Büdingen5, Gaelle Klingelschmitt5, Anthony Traboulsee6, Takashi Yamamura7 (1.Hôpital de Hautepierre, France, 2.Mayo Clinic, 3.Chugai Pharmaceutical Co., Ltd, Tokyo, 4.Chugai Pharma USA LLC, 5.F. Hoffmann-La Roche Ltd, 6.University of British Columbia, 7.National Center of Neurology and Psychiatry)

Abstract password authentication.
Password is written on a pocket program and name badge.

Password